SCHEMBL13335019

SCHEMBL13335019

Cc1cnc2c(ncn2C)c1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA1 P30542 2/20 0.47
▸ ADORA2A P29274 1/20 0.47
▸ YTHDC1 Q96MU7 2/20 0.44
▸ CCR1 P32246 1/20 0.40
▸ CCR5 P51681 1/20 0.40
▸ CCR8 P51685 1/20 0.40
▸ CDK1 P06493 4/20 0.39
▸ CYP1A2 P05177 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ NFKB1 P19838 1/20 0.37
▸ THPO P40225 1/20 0.37
▸ PMP22 Q01453 1/20 0.37
▸ PIK3CG P48736 1/20 0.36
▸ PIK3C3 Q8NEB9 1/20 0.36
▸ CCNB1 P14635 1/20 0.34
▸ CCNE1 P24864 1/20 0.34
▸ CDK2 P24941 1/20 0.34
▸ PDE4A P27815 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25472935 0.79 ADORA1 (0.44) ADORA1ADORA2AYTHDC1CDK1CYP1A2
SCHEMBL12923695 0.76 ADORA2A (0.50) ADORA1ADORA2ACCR1CCR5CCR8
SCHEMBL800728 0.72 ADORA1 (0.46) ADORA1ADORA2AYTHDC1CCR1CCR5
SCHEMBL3933146 0.72 PI4KA (0.51) —
SCHEMBL441875 0.70 ADORA1 (0.62) ADORA1ADORA2AYTHDC1CDK1CYP1A2
SCHEMBL27404283 0.68 CCR1 (0.34) ADORA1ADORA2ACCR1CCR5CCR8
SCHEMBL25667797 0.68 ALDH1A1 (0.42) ADORA1ADORA2AGRM5
SCHEMBL14196788 0.67 CDK1 (0.44) ADORA1ADORA2AYTHDC1CDK1CCNB1
SCHEMBL13011009 0.67 CCR1 (0.47) CCR1CCR5CCR8HSP90AA1
SCHEMBL12332534 0.67 ADORA1 (0.48) ADORA1ADORA2AYTHDC1CDK1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100120706-A1 Macrolides Useful Against Inflammatory and Allergic Diseases BASILEA PHARMACEUTICA AG (CH) 2010-05-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120706-A1 Macrolides Useful Against Inflammatory and Allergic Diseases HRH4, HRH2, IL4 ADORA1 789/4885ADORA2A 1843/4885YTHDC1 2105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback